Recurrent Lymphoepithelioma of the Nasopharynx Completed Phase 1 Trials for Hydroxyurea (DB01005)

IndicationStatusPhase
DBCOND0029500 (Recurrent Lymphoepithelioma of the Nasopharynx)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00023959Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck CancerTreatment